These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1640362)

  • 1. Performance of a modified starch hydrophilic matrix for the sustained release of theophylline in healthy volunteers.
    Vandenbossche GM; Lefebvre RA; De Wilde GA; Remon JP
    J Pharm Sci; 1992 Mar; 81(3):245-8. PubMed ID: 1640362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption of theophylline from a sustained-release theophylline tablet formulation, Theo-Dur.
    Takagi K; Hasegawa T; Ogura Y; Yamaki K; Suzuki R; Satake T; Imaeda N; Mizukami Y
    Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):530-5. PubMed ID: 3429057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.
    Hurwitz A; Karim A; Burns TS
    J Clin Pharmacol; 1987 Nov; 27(11):855-61. PubMed ID: 3429692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theophylline absorption from two sustained-release products. Implications for therapeutic drug monitoring.
    Rogers RJ; Wiener MB; Hill MR; Szefler SJ
    Am Rev Respir Dis; 1987 Nov; 136(5):1168-73. PubMed ID: 3674579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium.
    Rojanasthien N; Kovjiriyapan K; Manorot M; Pothirat C
    Asian Pac J Allergy Immunol; 2001 Jun; 19(2):69-78. PubMed ID: 11699723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
    González MA; Kisicki J; Straughn AB
    Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans.
    Raz I; Bialer M; Salame K; Bar-On H
    Eur J Clin Pharmacol; 1984; 26(3):401-3. PubMed ID: 6734702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption of theophylline from enteric coated and sustained release formulations in fasted and non-fasted subjects.
    Osman MA; Patel RB; Irwin DS; Welling PG
    Biopharm Drug Dispos; 1983; 4(1):63-72. PubMed ID: 6839003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation.
    Hussein Z; Friedman M
    Pharm Res; 1990 Nov; 7(11):1167-71. PubMed ID: 2293217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invivo absorption behaviour of theophylline from starch-methyl methacrylate matrix tablets in beagle dogs.
    Fernández-Campos F; Ferrero C; Colom H; Jiménez-Castellanos MR
    Int J Pharm; 2015 Jan; 478(2):684-92. PubMed ID: 25476254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of four slow-release theophylline formulations in the beagle dog.
    Koritz GD; McKiernan BC; Neff-Davis CA; Munsiff IJ
    J Vet Pharmacol Ther; 1986 Sep; 9(3):293-302. PubMed ID: 3761420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.
    Ochoa L; Igartua M; Hernández RM; Solinís MA; Gascón AR; Pedraz JL
    Eur J Pharm Biopharm; 2010 Jun; 75(2):232-7. PubMed ID: 20159037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men.
    Dockhorn RJ; Cefali EA; Straughn AB
    Ann Allergy; 1994 Mar; 72(3):218-22. PubMed ID: 8129214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system.
    González MA; Straughan AB
    Clin Ther; 1994; 16(5):804-14. PubMed ID: 7859239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption properties of two theophylline sustained-release products in smokers.
    Miller R; Rheeders M
    S Afr Med J; 1984 Jun; 65(26):1045-8. PubMed ID: 6740419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.
    Steinijans VW; Zech K; Fischer R
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):624-30. PubMed ID: 6668100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance.
    Mucklow JC; Kuhn S
    Br J Clin Pharmacol; 1985 Dec; 20(6):589-96. PubMed ID: 4091990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of moricizine on the pharmacokinetics of single-dose theophylline in healthy subjects.
    Pieniaszek HJ; Davidson AF; Benedek IH
    Ther Drug Monit; 1993 Jun; 15(3):199-203. PubMed ID: 8332999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of hyperlipidic food on the kinetics of slow-release formulations of theophylline.
    Brazier JL; Benchekroun Y; Gillet A; Andre C
    Eur J Clin Pharmacol; 1989; 37(1):85-90. PubMed ID: 2591470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of a generic slow-release theophylline tablet in children.
    Kanthawatana S; Ahrens RC; McCubbin M; Bronsky E; Blake K; Hendeles L
    J Pediatr; 1994 Dec; 125(6 Pt 1):987-91. PubMed ID: 7996375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.